Dalotuzumab

• CAT Number: I042254
• CAS Number: 1005389-60-5
• Molecular Weight: 146.4 (kDa)
• Purity: ≥95%

Dalotuzumab (Cat No.: I042254) is a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in tumor growth, survival, and resistance to therapy. By binding to IGF-1R, dalotuzumab blocks its activation and downstream signaling pathways, thereby inhibiting cancer cell proliferation. It has been investigated in clinical trials for various malignancies, including breast, pancreatic, and colorectal cancers. Dalotuzumab is a valuable agent in oncology research, particularly for exploring IGF-1R as a therapeutic target in solid tumors.

Reference

[1]. Goetsch L, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005 Jan 10;113(2):316-28.
[Content Brief]

[2]. Bitelman C, et al. IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett. 2013 Jul 10;335(1):153-9.
[Content Brief]

[3]. Scartozzi M, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010 Jun;12(3):361-71.
[Content Brief]